Kimberly-Clark buys troubled Tylenol maker Kenvue for $48.7 billion
Kimberly-Clark agreed to acquire Johnson & Johnson (J&J) consumer health spinoff Kenvue for $48.7 billion. Kimberly-Clark, one of the largest U.S. consumer health companies, said it would acquire all of Kenvue’s common stock, creating a conglomerate that will generate annual revenue of $32 billion. Under the deal, shareholders of Kenvue, a company J&J spun off…